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Hypoxia is a common feature in most of the solid tumors including head and neck squamous cell carcinoma (HNSCC). Hypoxia
reflects the imbalance between oxygen consumption by the rapidly proliferating cancer cells and the insufficient oxygen delivery
due to poor vascularization and blood supply. The hypoxic microenvironment in the HNSCC contributes to the development of
aggressive carcinoma phenotype with high metastatic rate, resistance to therapeutic agents, and higher tumor recurrence rates,
leading to low therapeutic efficiency and poor outcome. To overcome the therapeutic resistance due to hypoxia and improving
the prognosis of the HNSCC patients, many approaches have been examined in laboratory studies and clinical trials. In this short
paper, we discuss the mechanisms involved in the resistance of radiotherapy and chemotherapy in hypoxic condition. We also
exploit the molecular mechanisms employed by the HNSCC cells to adapt the hypoxic condition and their tumorigenic role in
head and neck, as well as the strategies to overcome hypoxia-induced therapeutic resistance.
1. Introduction
Hypoxic microenvironment is frequently found in solid
tumors and is known as a negative prognostic factor in head
and neck squamous cell carcinoma (HNSCC). Development
of hypoxic microenvironment is caused by the imbalance
between oxygen consumption and oxygen delivery. The
rapidly proliferating HNSCC has insufficient vascularization
with poor blood supply. Limiting blood supply network in
the rapidly proliferating tumor region limits oxygen diffu-
sion, resulting in the development of hypoxic region. The
hypoxic stress stimulates solid tumor to unregulate expres-
sion of a variety of oncogenes such as hypoxia-inducible
factor and vascular endothelial growth factor, which enhance
irregular vascular endothelial cell proliferation and differ-
entiation. The expression of endothelial cell regulators will
enhance the growth of new blood capillaries, leading to the
development of neovascularized tumors in head and neck
[1]. The microvessel network in the solid tumor is physio-
logically different in comparison with the normal counter-
part. Physically, the vasculatures in solid tumors are dis-
tended with leaky wall. In terms of efficiency, the blood
flow in these newly growth vessels is slow with poor oxygen
delivery rate. At present, there is no precise definition of
hypoxic oxygen tension in solid tumor as it is highly varying
depending on the tumor size and location. The oxygen
tension in solid tumor is expressed as partial pressure of
oxygen (pO2) with a threshold of 10mmHg [2]. In solid
tumors, HNSCC is characterized with low oxygen tension.
The oxygenation levels in head and neck could be measured
at the enlarged cervical lymph nodes and the primary tumor
with the use of oxygen-sensitive electrodes and derived from
the histography. Becker measured the oxygen tension of pri-
mary HNSCC patients and observed that the median tumor
pO2 was 8.6± 5.4mmHg [3]. In advanced HNSCC patients,
the measured pO2 was lower. In 67 stage II-III squamous cell
carcinoma patients, it was found that pO2 values ≤ 2.5 was a
significant prognostic factor for local-regional tumor control
and outcome of radiotherapy [4]. Although total tumor
volume is a well-known prognostic factor in HNSCC, it is
now recognized that the hypoxic volume at the primary site
is the key determining factor [5]. Acute hypoxic stress would
lead to the development of aggressive cancer phenotype with
high metastatic rate, resistance to therapeutic agents, and
higher tumor recurrence rates [6–12]. Prolonged deprivation
of oxygen will lead to chronic hypoxic stress, leading to
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tumor necrosis. These features are also observed in HNSCC
and now regarded as a major contributing factor leading to
the poor outcome [6, 7, 13]. The aim of this short review
article is to briefly discuss the mechanisms involved in thera-
peutic resistance in hypoxic condition. Furthermore, we will
exploit the molecular mechanisms employed by the HNSCC
cells to adapt the hypoxic condition and their tumori-
genic role in head and neck.
2. Hypoxia Contributes to the Poor
Therapeutic Outcome in HNSCC
Apart from surgical resection, radiotherapy and chemother-
apy are the most common treatment methods in HNSCC
patients. The treatment efficacy can be improved by either
altered fractionated radiotherapy or concomitant chemora-
diotherapy [14]. Accumulated evidence suggested that
HNSCC with sufficient oxygen supply has a better responsive
rate to radiation in comparison with the hypoxic tumor
[15, 16]. Furthermore, oxygen stress could trigger tumor cells
to proliferate and allow them to undersurvive cytotoxic-fac-
tor assault [17].
2.1. Hypoxia Contributes to Radioresistance in HNSCC. The
tumor cells in the hypoxic region are shown to bemore resist-
ant to the radiotherapy compared with well-oxygenated
ones [18–20]. It has long been known that the develop-
ment of hypoxic region in the solid tumor will affect the
effect of radiation in killing the cancer cells [21]. Hypoxic
radioresistance is first described in 1909. The condition is
specific to solid tumor and becomes severe when the oxygen
tension of the tumor was 5mmHg or less [22]. Quantitative
measurement suggested that cells in a hypoxic condition
with pO2 of 0.5–20mmHg were easier to demonstrate the
resistant phenotype [23]. In solid tumor, radiation sensitivity
is determined by 2 factors: the intrinsic radiosensitivity of the
tumor cells and the degree of hypoxia [24]. Radiation kills
the cancer cells by generating reactive hydroxyl free radical
with the cellular water. In the presence of oxygen, the reactive
free radical will react with the DNA strand, resulting in
permanent DNA damage. Oxygen will supply electron to the
damaged DNA strand and destabilize the strand break. This
enhancement effect of oxygen in radiation therapy is known
as oxygen enhancement ratio. Without the electron supply
from oxygen under hypoxic condition, the DNA damages
induced by radiation could be repaired by the cancer cells.
Furthermore, the free radicals generated by the radiation
could be neutralized by a sulfhydryl-containing compound
[25]. Therefore, in order to reach the same treatment out-
come, higher dose of radiation is required in hypoxic can-
cers in comparison with the anoxic one. In comparison
with chronic hypoxia, acute hypoxia was suggested to have
a greater contribution to the treatment resistance. This may
be due to the higher probability of cell survival and prolife-
ration resuming after oxygen and nutrients deprivation for
a limited time [26]. In 1999, Brizel et al. reported that in
poorly oxygenated HNSCC patients, 2-year locoregional
control, disease-free survival rate, and overall survival rate
were significantly lower in comparison with those in the
well-oxygenated HNSCC patients [18]. Hypoxia could be
developed by smoking. It has been suggested that smoking
restricted the radiotherapeutic effect, which might be due to
increased level of carboxyhemoglobin and reduced oxygen
supply in blood flow of smoking patients [27].
2.2. Hypoxia Contributes to Chemoresistance in HNSCC.
Cancer cell could develop resistance to the chemotherapeutic
agents and the hypoxic stress is a promoting factor. Hypoxia-
induced chemoresistance was firstly reported in the 1980s,
suggesting that tumor cells in the chronically hypoxic or
severe hypoxic conditions may be chemoresistant [28, 29].
Sakata et al. also proved the relation between hypoxia and
chemoresistance in the mouse breast cell line (EMT6/Ro
cells) [30]. In 2001, Matthews et al. treated human breast
carcinoma cells and mouse melanoma cells with different
chemotherapeutic drugs after exposing the cells to different
concentration of oxygen. They found that hypoxia could
promote resistance of the tumor cells to the chemotherapeu-
tic drugs including doxorubicin and 5-fluorouracil [31]. In
HNSCC, Gabalski et al. observed selective survival of hypoxic
tumor cells after chemotherapy [32]. In hypoxic tumor,
the chemotherapeutic drugs are less effective. One major
reason is the inefficient delivery of the cytotoxic drugs to the
tumor sites. As the hypoxic tumor usually has poor vascular
structure, diffusion distance of the chemotherapeutic agents
to the tumor will be increased, leading to the low delivery rate
of the chemotherapeutic drug to the tumor [33–35]. In this
circumstance, it is not the tumor itself that develops resis-
tance mechanisms against the applied therapeutic agent. It
is the diminished concentration of chemotherapeutic agents
in the hypoxic regions resulting in the poor therapeutic
efficiency. On the other hand, it was found that the drugs
targeting rapidly dividing cells are not useful in eliminating
the hypoxic tumors. When the hypoxic region is developed
inside the tumor, some hypoxic cells will reduce their
proliferation rate and hence reduce the responsiveness to the
chemotherapeutic agents [33, 35]. Some of the chemother-
apeutic drugs such as carboplatin and doxorubicin were
oxygen dependent. These drugs showed low efficiency in
the hypoxic condition, also leading to the chemoresistance
[34]. Recently, it was discovered that the existence of cancer-
derived stem cell is one of the contributing factors leading to
the development of drug resistance in HNSCC [36]. In the
HNSCC bulk, there is a rare cell population called cancer
stem cells. The cancer stem cells in HNSCC have a higher
tumor-forming ability in comparison with the anoxia coun-
terpart [37]. The HNSCC stem cells were first reported in
2007 and have the characteristic expression of surface marker
CD44 [37]. Apart fromCD44, it was later found that HNSCC
stem cell would express a subset of stem cell markers includ-
ing CD133 and aldehyde dehydrogenase [38]. These cancer-
derived stem cells have exhibited the ability of self-renewal
of normal stem cell and could prevent themselves from
entering the cycle of differentiation. In addition, cancer stem
cells could survive in fluctuating hypoxic conditions [39].
These cancer stem cells have low proliferation rate and hence
are not responsive to the division-dependent therapeutic
agents.
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3. Genetic Factors Involved in Therapeutic
Resistance in Hypoxic Condition in HNSCC
Genetic alterations due to hypoxia were associated with
radioresistance and chemoresistance in HNSCC. These
altered genes and their encoding proteins in hypoxic condi-
tion could also serve as the markers for the hypoxia and pro-
gnostic prediction.
3.1. Hypoxia-Induced Factors-1 Alpha (HIF-1α). Among all
the altered factors involved in hypoxia-induced therapeutic
resistance, the hypoxia-induced factors-1 (HIF-1) played a
central role. HIF-1 is a heterodimeric basic helix-loop-helix
transcription factor composed of two subunits, HIF-1α and
HIF-1β. HIF-1α is the central regulatory component, which
is firstly described to play a key role in mediating oxygen-
dependent transcriptional responses by Wang et al. in 1995
[40].
Usually, HIF-1α protein only existed in the hypoxic con-
dition, because it was rapidly degraded by ubiquitination
under normoxia [40]. Hypoxia suppressed the degradation
of HIF-1α protein andmade it translocate into the tumor cell
nuclei from cytoplasm and then form the HIF-1 with HIF-
1β. After binding to the hypoxia responsive element (HRE)
located in the enhancer and promoter regions of its target
genes, HIF-1 dysregulated the expression of its downstream
genes, which were more than 100 and were reported to be
involved in angiogenesis, glucosemetabolism, pH regulation,
matrix metabolism, proliferation, and apoptosis in the
tumors [41].
According to the report from Koukourakis et al., HIF-1α
was not detected in the head and neck mucosa in the non-
cancerous cases, while it was expressed in the tumor tissues
[42]. On the other hand, Costa et al. investigated the hypoxic
markers by immunochemical method in 25 adenoid cystic
carcinoma cases and they found that HIF-1α could be
detected in all the tumor tissues [43]. Therefore, HIF-1α was
thought to be an optimal hypoxic marker and a prognostic
predictor for the HNSCC.
In most studies, HIF-1α overexpression was associated
with poor outcomes response to the treatment. Aebersold et
al. reported their study on the association of HIF-1α with the
prognosis of the oropharyngeal carcinoma cases after radio-
therapy. In this study, 98 cases were processed for immu-
nohistochemistry, and 94% of them showed overexpression
of HIF-1α in comparison with the normal control [44].
Moreover, higher HIF-1α immunoreactivity was related to
the lower rate of complete remission of the primary tumor,
lymph node metastases, local failure-free survival, disease-
free survival, and overall survival. In 2009, Roh et al. reported
their study on the prognostic value of hypoxic markers in
T2-staged oral tongue cancer. Results suggested that HIF-
1α overexpression was significantly correlated with the poor
disease-specific survival rates [45]. In a study on the radio-
therapeutic effect on early-stage glottic carcinoma, HIF-1α
overexpression was closely correlated with the worse local
control of tumor in the early-stage glottis carcinoma after
radiotherapy [46].
However, there was contrast result, reported by Beasley
et al., showing a positive relationship between HIF-1α
expression and disease-free and overall survival in the sur-
gically resected patients with or without postoperative radio-
therapy. This might because that the effect of reduced pro-
liferation and increased apoptosis induced by HIF-1α under
hypoxia could overcome the effect of enhancing tumor
growth by HIF-1α targeted genes in some conditions [47].
Fillies et al. compared the HIF-1α expression by immunos-
taining of early-stage oral floor squamous cell carcinomas,
with the tumor size, tumor differentiation, lymph node
status, and disease-free and overall survival. They found that
low HIF-1α expression indicated a poor disease-free and
overall survival, while it showed no obvious effect to the
tumor size, tumor differentiation, and lymph node status
[48]. On the other hand, HIF-1α was not necessarily associ-
ated with prognosis of the surgically treated supraglottic car-
cinoma cases, while it was positively correlated with the T-
classification of tumor [49].
3.2. Carbonic Anhydrase IX (CA IX). Carbonic anhydrase
IX (CA IX) is a transmembrane glycoprotein [50], which is
firstly thought as a membrane-bound protein “MN protein”
on the surface of the HeLa human cervical carcinoma cell
line [51, 52]. This protein in the tumor was induced by
the hypoxia, while low expression was detected in normoxic
tumor region and normal tissues [53–55]. Its encoding gene
CA9 was the downstream gene of HIF-1α and PI3K, and its
expression was upregulated by increased transcriptional acti-
vity of HIF-1α and PI3K activation [56, 57].
CA IX was reported to be overexpressed in both three
HNSCC cell lines under hypoxia and tumor tissues in
comparison with the paired normal ones. Moreover, it is
located in the perinecrotic area of tumor tissues, where were
under hypoxia [50]. It could catalyze the reversible hydration
of carbon dioxide to carbonic acid. Its overexpression could
reduce the pH value in the extracellular environment, which
would alter the uptake and effect of anticancer drugs. With
the overexpression of CA IX, the toxicity of weak acidic
drugs such as fluorouracil would be enhanced [58] while the
toxicity and intracellular accumulation of weak basic drugs
such as doxorubicin would be reduced [59].
It was also reported that the carcinoma cells proliferation
could be promoted as a result of simultaneous upregulation
of proliferative factor-IdUrd and CA IX due to the colocaliza-
tion of IdUrd and CA IX in HNSCC [60]. CA IX was widely
studied as a predictor, usually coupled with other factors,
for prognosis of HNSCC patients. In 2001, Koukourakis et
al. reported their study with samples of 75 HNSCC patients.
Strong cancer cell membrane and cytoplasmic CA IX
expression were detected by immunostaining in 26.6% cases,
and these cases showed poorer local relapse-free survival
and overall survival rate in comparison with the ones with
no or low expression of CA IX [61]. Kim et al. reported that
the combined high expression of CA IX and Ki 67 indicated
a poorer outcome of the patients with squamous cell
carcinoma of the tongue. They studied 60 cases and found
that the cases with both CA IX and Ki 67 overexpression
were related to the lower overall survival rate and shorter
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disease-free survival period in comparison with the ones
with either low expression of CA IX or Ki 67 [62]. In the
meta-analysis by Peridis et al., low HIF-1α/CAIX expression
was significantly correlated with a better prognosis for oral
squamous cell carcinoma patients [63].
However, some studies showed a reverse relationship
between the CA IX and prognosis of HNSCC. According
to the study by Eckert et al., oral squamous cell carcinoma
patients with higher HIF-1α and low CA IX expression
showed lower overall survival rate and higher risk of tumor-
related death by 4.97-fold in comparison with the patients
with low expression of both these proteins [64].
3.3. Vascular Endothelial Growth Factor (VEGF). Vascular
endothelial growth factor (VEGF) was at first described as
tumor “vascular permeability factor” (VPF) in 1983, which
could induce vascular leakage, leading to a high permeability
of tumor blood vessels [65]. In 1989, the purified VPF was
reported as a regulatory protein for blood vessels growth
with modification to the present name [64, 66–68]. In
HNSCC, VEGF was reported to be involved in the pathway
between tumor hypoxia and neoangiogenesis and as a pre-
dictor for the poor prognosis. In a study with 133 HNSCC
cases by Dunst et al., tumor oxygenation, tumor hypoxic
volume, and serum VEGF level were measured. They found
that serum VEGF levels were significantly correlated with
hypoxic tumor volume, indicating that the hypoxic condition
is the most important influencer to the expression of VEGF
[69]. Mohamed et al. also confirmed this result. They
studied the relationship between the HIF-1α and VEGF
on 3 human oral squamous carcinoma cell lines under
hypoxia. Significantly higher expression of both HIF-1α
and VEGF in mRNA and protein level were observed in
all the hypoxic oral squamous carcinoma cell lines under
hypoxia [1]. In 2007, Liang et al. reported their study on the
detection of HIF-1α and VEGF expression in 65 cases of oral
squamous cell carcinoma. 66.2% and 52.3% of these cases
showed HIF-1α and VEGF overexpression, respectively. In
these cases, higher lymphatic vessel density, regional lymph
nodal involvement, and advanced UICC TMN classification
were found [70]. Furthermore, the cases with combined
overexpression of these two proteins showed a higher blood
vessel density. Beside the oral squamous cell carcinoma, this
tight correlation between HIF-1α and VEGF were also found
in laryngeal squamous cell carcinoma [71]. In their study,
higher expression of VEGF was also associated with more
lymph node involvement and higher recurrence rate. Similar
correlation was reported in the nasopharyngeal carcinoma by
Hui et al. [72].
4. Strategies to Overcome Hypoxia-Induced
Therapeutic Resistance
There are different kinds of strategies such as enhancing oxy-
gen delivery, hypoxic radiosensitizers, and hypoxic cytotoxin
to overcome hypoxia-induced therapeutic resistance.
4.1. Enhancing Oxygen Delivery. Hyperbaric oxygen (HBO)
(100% oxygen) breathing and carbogen (95% oxygen plus
5% carbon dioxide) breathing have been used to elevate the
oxygen partial pressure in tissues, thus decreasing chronic
hypoxia [73, 74]. HBO therapy refers to inhalation of 100%
oxygen at elevated pressure (>1.5 atmospheres absolute),
resulting in elevated oxygen level in plasma and tissues [75].
Henk reported that combined 10 fractions of radiotherapy
with HBO resulted in higher survival and local control rates
in comparison with 30 fractions of radiotherapy in 104
patients with HNSCC, suggesting that HBO augmented the
effects of radiotherapy [76]. Ferguson et al. found that HBO
therapy could be used as an effective adjunctive treatment
modality for laryngeal radionecrosis [77]. In a follow-up
clinical study, Haffty et al. evaluated the long-term outcome
of treatment with hypofractionated radiation and HBO at
4 atmospheres of pressure in patients with locally advanced
laryngeal carcinoma [78]. Clinical data showed that this
treatment program resulted in a response rate and long-term
tumor control rate comparable to more protracted radiation
schedules, indicating that HBO therapy contributed to local
control of advanced laryngeal carcinoma [78].
Carbogen was suggested as an alternative to pure oxygen
because carbon dioxide had vasodilating property [73].
Kaanders et al. carried out a phase II clinical study to
assess the effects of ARCON (accelerated radiotherapy with
carbogen and nicotinamide) treatment in 215 patients with
advanced HNSCC [79]. Nicotinamide was used because it
decreased the intermittent closure of blood vessels, leading
to the reduction of acute hypoxia [80]. It has been found
that ARCON treatment resulted in the local control rates of
80% for larynx, 60% for hypopharynx, 87% for oropharynx,
and 29% for oral cavity in patients with T3 and T4 tumors.
ARCON treatment also led to the regional control rates of
100% for N0, 93% for N1, and 74% for N2 disease [80].
These results indicated that ARCON treatment exhibited
high local and regional control rates in patients with
advanced HNSCC.
4.2. Hypoxic Cell Radiosensitizers. Two kinds of hypoxic
cell radiosensitizer, misonidazole and nimorazole, have been
reported [79, 81]. These two compounds mimic the effects
of oxygen due to their electron affinity, resulting in the
increase in DNA damage and restoration of radiosensitivity.
Overgaard et al. assessed the efficacy of misonidazole in 626
patients with pharynx and larynx carcinoma [79]. It has
been reported that patients with pharynx carcinomas treated
with misonidazole exhibited a significantly better control
rate than patients treated with another hypoxic cell radiosen-
sitizer, placebo. However, the clinical use of misonidazole was
limited because it caused significant peripheral neuropathy
in 26% of the patients [79].
Cottrill et al. evaluated the outcome of combined nimo-
razole with continuous hyperfractionated accelerated radia-
tion therapy (CHART) in 22 patients with locally advanced
stage IV HNSCC. Clinical data showed that combined
treatment led to higher tumor responses in comparison
with CHART regimen alone [82]. Moreover, nimorazole
did not enhance the severity of acute normal tissue radi-
ation effects [82]. Subsequently, the same research group
carried out a phase II clinical study with 61 patients with
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advanced stage III or IV HNSCC [83]. Combination of
nimorazole and CHART caused the same normal tissue
effects as CHART. Furthermore, combination of CHART
and nimorazole resulted in the higher local-regional control
rates in comparison with CHART alone, suggesting that
nimorazole displayed inhibitory effects on HNSCC [83]. In
a randomized double-blind phase III clinical study with 422
patients with pharynx and supraglottic larynx carcinoma,
Overgaard et al. assessed the efficacy and tolerance of
nimorazole in combination with primary radiotherapy [81].
Clinical data showed that patients treated with nimorazole
displayed a better locoregional control rate, endpoints of
final locoregional control (including surgical salvage), and
overall survival than patients treated by another hypoxic
cell radiosensitizer, placebo [81]. Furthermore, administra-
tion of nimorazole had no major side effects to patients
[81]. These results indicated that nimorazole enhanced the
inhibitory effects of radiotherapy in patients with pharynx
and supraglottic larynx carcinoma.
4.3. Hypoxic Cytotoxin. Tirapazamine, a hypoxic cell cyto-
toxin, displayed cytotoxicity in hypoxia cells but not in
normal cells [74]. When exposed in hypoxia conditions, tira-
pazamine was reduced to a reactive radical, which could lead
to single- and double-strand DNA breaks. In contrast, this
reactive radical was oxidized to the inert parent compound
in normoxia [74]. Rischin et al. performed a clinical study
to assess the effects of tirapazamine in combination with
cisplatin and radiation in patients with advanced HNSCC
[84]. Results from 18F misonidazole scans demonstrated
that hypoxia levels decreased in patients after treatment.
Clinical data also showed that combined tirapazamine with
cisplatin and radiotherapy led to good and durable clinical
responses with a 3-year failure-free survival rate of 69%,
a 3-year local progression-free rate of 88%, and a 3-year
overall survival rate of 69% [84]. In a randomized phase II
clinical trial carried out by Rischin et al. to select therapeutic
regimens for locally advanced HNSCC, it has been shown
that patients treated with tirapazamine/cisplatin/radiation
displayed higher three-year failure-free survival rates and
three-year locoregional failure-free rates than patients
treated with cisplatin/fluorouracil/radiation [85]. Further-
more, acute skin radiation reaction was less severe and pro-
longed in tirapazamine/cisplatin/radiation group than that
in cisplatin/fluorouracil/radiation group [85]. Cohen et al.
have also found that combined radiation with tirapazamine
and cisplatin resulted in long-term survival in a significant
proportion of patients [86].
5. Conclusion
Hypoxia is a common feature in HNSCC, which contributes
to the development of tumorous aggression and metastasis.
What’s more, it is reported to play a key role in the radioresis-
tance, the chemoresistance, and then the poor prognosis. In
view of that, the hypoxic condition should be an important
target in the HNSCC treatment. Removing the hypoxic
microenvironment by enhancing the oxygen delivery, as well
as improving the hypoxic cell death rate by using hypoxic cell
radiosensitizer and hypoxic cell cytotoxin, are proved to be
able to help to overcome the poor prognosis of HNSCC. On
the other hand, since HIF-1α and its downstream genes are
proved to play central roles in hypoxia-induced therapeutic
resistance in HNSCC, exploration for agents targeting to
these genes could be another orientation in improving the
therapeutic effect and the poor prognosis of HNSCC.
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